Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indivior Pact Buys Addex Time For Progressing Dipraglurant And Pipeline

Executive Summary

Addex Therapeutics says its licensing deal with Indivior to develop and commercialize its investigative addiction therapy ADX71441 'buys time' to find resources for progressing its own pipeline.

You may also be interested in...



Facing Up To A Patent Cliff: Indivior Plans For Loss of Suboxone Film Exclusivity

With sales of its largest-selling product under threat from generic competition, a couple of new products and cost cuts are put forward to reinvigorate Indivior, a leader in addiction therapies.

Addex Completes Turnaround, Prepares For Phase III Dyskinesia Study

Geneva, Switzerland-based Addex Therapeutics has raised CHF40m to pursue its novel negative allosteric modulator in a late-stage study for levodopa-induced dyskinesia associated with Parkinson's disease.

Addex Therapeutics Emerges From Under The Radar

Having had to retrench after a financial crisis four years ago, Swiss biotech Addex Therapeutics has been focusing on its in-house platform around allosteric modulation. CEO Tim Dyer speaks to Scrip in a video interview recorded at Biotech Showcase.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel